| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
219,000,000 |
| Market
Cap: |
12.66(B) |
| Last
Volume: |
5,049,814 |
Avg
Vol: |
1,602,835 |
| 52
Week Range: |
$51.18 - $66.59 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 144 |
| Guru Rank Value : 7.1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
9,299 |
39,259 |
138,275 |
| Total Sell Value |
$0 |
$603,781 |
$2,515,280 |
$10,787,547 |
| Total People Sold |
0 |
3 |
4 |
7 |
| Total Sell Transactions |
0 |
4 |
6 |
15 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flannelly Barry P |
EVP & General Manager US |
• – – |
2020-06-19 |
4 |
OE |
$73.21 |
$525,721 |
D/D |
7,181 |
43,043 |
|
- |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-06-19 |
4 |
AS |
$100.00 |
$142,300 |
D/D |
(1,423) |
23,661 |
|
-18% |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-06-19 |
4 |
OE |
$72.27 |
$102,840 |
D/D |
1,423 |
25,084 |
|
- |
|
| Iyengar Vijay K |
EVP GPS, BD, & Licensing |
• – – |
2020-06-19 |
4 |
AS |
$105.00 |
$825,930 |
D/D |
(7,866) |
24,901 |
|
-18% |
|
| Iyengar Vijay K |
EVP GPS, BD, & Licensing |
• – – |
2020-06-19 |
4 |
OE |
$72.86 |
$573,117 |
D/D |
7,866 |
32,767 |
|
- |
|
| Wenqing Yao |
EVP, Head of Discovery Chem |
• – – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
152,188 |
|
- |
|
| Stein Steven H |
EVP & Chief Medical Officer |
• – – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
98,354 |
|
- |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-06-12 |
4 |
OE |
$65.36 |
$8,301 |
D/D |
127 |
23,661 |
|
- |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-06-10 |
4 |
AS |
$94.19 |
$341,649 |
D/D |
(3,615) |
23,534 |
|
-5% |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-06-10 |
4 |
OE |
$65.36 |
$240,915 |
D/D |
3,615 |
25,726 |
|
- |
|
| Dhanak Dashyant |
EVP & Chief Scientific Officer |
• – – |
2020-06-08 |
4 |
AS |
$91.87 |
$88,287 |
D/D |
(961) |
19,987 |
|
-7% |
|
| Dhanak Dashyant |
EVP & Chief Scientific Officer |
• – – |
2020-06-08 |
4 |
OE |
$65.42 |
$62,869 |
D/D |
961 |
20,948 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-28 |
4 |
B |
$102.55 |
$205 |
I/I |
2 |
29,313,198 |
2.17 |
-6% |
|
| Friedman Paul A |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
256,813 |
|
- |
|
| Dixon Wendy L |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
14,061 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
I/I |
2,564 |
29,313,197 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
8,982 |
|
- |
|
| Fouse Jacqualyn A |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
4,601 |
|
- |
|
| Harrigan Edmund |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
1,946 |
|
- |
|
| Clancy Paul J |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
4,026 |
|
- |
|
| High Katherine A |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
1,421 |
|
- |
|
| Pasquale Maria E |
EVP & General Counsel |
• – – |
2020-05-11 |
4 |
OE |
$65.36 |
$8,366 |
D/D |
128 |
23,534 |
|
- |
|
| Dhanak Dashyant |
EVP & Chief Scientific Officer |
• – – |
2020-05-06 |
4 |
AS |
$96.84 |
$93,063 |
D/D |
(961) |
19,987 |
|
-11% |
|
| Dhanak Dashyant |
EVP & Chief Scientific Officer |
• – – |
2020-05-06 |
4 |
OE |
$65.42 |
$62,869 |
D/D |
961 |
20,948 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-04-28 |
4 |
OE |
$13.34 |
$533,600 |
I/I |
40,000 |
29,311,915 |
|
- |
|
1552 Records found
|
|
Page 17 of 63 |
|
|
0.49 (0.86%) 
